ADVFN Logo ADVFN

Wir konnten keine Ergebnisse für:
Stelle sicher, dass deine Schreibweise korrekt ist oder versuche deine Suche zu erweitern.

Trends

Toplisten

Es scheint, dass du nicht eingeloggt bist.
Klicke auf den Button unten, um dich einzuloggen und deine zuletzt angesehenen Aktien zu sehen.

Hot Features

Registration Strip Icon for discussion Registrieren Sie sich, um in unseren aktiven Foren mit gleichgesinnten Anlegern zu diskutieren.

IMUX Immunic Inc

1,30
0,00 (0,00%)
Vor Marktöffnung
Zuletzt aktualisiert: 10:00:00
Verzögert um 15 Minuten
Name Symbol Markt Aktientyp
Immunic Inc IMUX NASDAQ Common Stock
  Änderung Änderung % Aktuell Zeit
0,00 0,00% 1,30 10:00:00
Handelsbeginn Niedrig Hoch Schlusskurs Handelsende
1,30
more quote information »

Aktuelle News

Datum Zeit Quelle Überschrift
01.5.202412:30PRNUSImmunic, Inc. to Announce Financial Results for the First..
30.4.202412:30PRNUSImmunic Announces Publication of Extended Data From Phase 2..
04.4.202412:30PRNUSImmunic to Host MS R&D Day and Participate in Investor..
20.3.202411:30PRNUSImmunic Receives Notice of Allowance for..
08.3.202422:05EDGAR2Form 8-K - Current report
07.3.202412:30PRNUSImmunic to Participate in Investor and Scientific..
07.3.202403:52EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202403:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202403:51EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202403:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202403:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
07.3.202403:50EDGAR2Form 4 - Statement of changes in beneficial ownership of..
29.2.202412:30PRNUSImmunic Presents Data From Phase 2 CALLIPER and CALVID-1..
22.2.202412:38EDGAR2Form 10-K - Annual report [Section 13 and 15(d), not S-K..
22.2.202412:35EDGAR2Form 8-K - Current report
22.2.202412:30PRNUSImmunic, Inc. Reports Year End 2023 Financial Results and..
15.2.202412:30PRNUSImmunic, Inc. to Announce Financial Results for the Year..
14.2.202422:05EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202414:47EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
14.2.202413:55EDGAR2Form SC 13G/A - Statement of acquisition of beneficial..
13.2.202422:36EDGAR2Form S-3 - Registration statement under Securities Act of..
05.2.202414:30EDGAR2Form DEF 14A - Other definitive proxy statements
01.2.202412:30PRNUSImmunic to Participate in Investor and Scientific..
24.1.202423:05EDGAR2Form PRE 14A - Other preliminary proxy statements
19.1.202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.1.202422:07EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.1.202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.1.202422:06EDGAR2Form 4 - Statement of changes in beneficial ownership of..
19.1.202422:05EDGAR2Form D - Notice of Exempt Offering of Securities
16.1.202422:12EDGAR2Form SC 13G - Statement of acquisition of beneficial..
10.1.202415:00EDGAR2Form SC 13G - Statement of acquisition of beneficial..
05.1.202412:41EDGAR2Form 8-K - Current report
05.1.202412:35PRNUSImmunic Highlights 2023 Accomplishments and Upcoming..
05.1.202412:30PRNUSImmunic, Inc. Announces Private Placement of up to $240..
21.12.202314:30EDGAR2Form 8-K - Current report
22.11.202322:20EDGAR2Form S-3 - Registration statement under Securities Act of..
21.11.202312:30PRNUSImmunic Receives Notice of Allowance for United States..
14.11.202312:38EDGAR2Form 8-K - Current report
14.11.202312:30PRNUSImmunic, Inc. Reports Third Quarter 2023 Financial Results..
07.11.202312:30PRNUSImmunic to Announce Financial Results for the Third Quarter..
02.11.202311:30PRNUSImmunic Receives Notice of Allowance for United States..
26.10.202312:30PRNUSImmunic to Participate in Scientific and Industry..
18.10.202322:05EDGAR2Form 8-K - Current report
16.10.202312:30PRNUSImmunic Presents Data From Phase 2 CALDOSE-1 Trial of..
15.10.202312:30PRNUSImmunic Presents Data From Phase 1b Clinical Trial of..
11.10.202312:30PRNUSImmunic Presents Data From Phase 2 EMPhASIS Trial of..
10.10.202314:48EDGAR2Form 8-K - Current report
09.10.202322:01PRNUSImmunic Reports Positive Interim Data from Phase 2 CALLIPER..
04.10.202312:30PRNUSImmunic to Participate in Scientific Conferences in October
06.9.202312:30PRNUSImmunic to Participate in Industry and Investor Conferences..

Kürzlich von Ihnen besucht

Delayed Upgrade Clock